antidepressant medications, flexible drug choice — Competitive Intelligence Brief

antidepressant medications, flexible drug choice (antidepressant medications, flexible drug choice) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry.

phase 3 Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter Psychiatry Small molecule

Target snapshot

antidepressant medications, flexible drug choice (antidepressant medications, flexible drug choice) — Sir Mortimer B. Davis - Jewish General Hospital. This antidepressant medication works by increasing the levels of certain neurotransmitters in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
antidepressant medications, flexible drug choice TARGET	antidepressant medications, flexible drug choice	Sir Mortimer B. Davis - Jewish General Hospital	phase 3	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter
Fetzima	LEVOMILNACIPRAN	AbbVie	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2013-01-01
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Pristiq	desvenlafaxine	Alembic Pharms Ltd	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2008-01-01
Celexa	CITALOPRAM	AbbVie	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Racemic Sibutramine	SIBUTRAMINE		marketed	Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic	Sodium-dependent serotonin transporter	1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class